

# Stanford

---



## Sandra Horning

Professor of Medicine, Emerita  
Medicine - Oncology

### Bio

---

#### ACADEMIC APPOINTMENTS

- Emeritus Faculty, Acad Council, Medicine - Oncology

#### ADMINISTRATIVE APPOINTMENTS

- President-Elect, ASCO, (2004-2005)
- President, ASCO, (2005-2006)

#### HONORS AND AWARDS

- Alwin C. Rambar-James B. D. Mark Award for Excellence in Patient Care, Stanford University School of Medicine (2000)

### Research & Scholarship

---

#### CURRENT RESEARCH AND SCHOLARLY INTERESTS

The objectives of the clinical research program are:

1. to improve therapeutic outcomes and/or reduce complications of treatment, and
2. to further elucidate the underlying biology of Hodgkin's disease (HD) and the non-Hodgkin's lymphomas (NHL).

The research program is highly collaborative and includes ongoing clinical trials with myeloablative therapy in HD and NHL with the Bone Marrow Transplant team, combined modality trials in HD with Radiation Oncology, clinical-pathologic correlative studies with Pathology, and drug development with an emphasis on targeted therapy for B-cell lymphoma (anti-CD20) with industrial collaborators.

Dr. Horning is chairman of the Lymphoma Committee for the Eastern Cooperative Oncology Group, a forum for extending pilot studies to multi-institutional trials.

Dr. Horning supervises a sophisticated multi-relational Lymphoma Database which has information on over 15,000 patients, an excellent resource for prospective and retrospective clinical investigations

#### CLINICAL TRIALS

- 90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL, Not Recruiting
- A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma, Not Recruiting
- A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma, Not Recruiting
- A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies, Not Recruiting
- A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas, Not Recruiting

- A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma, Not Recruiting
- A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL, Not Recruiting
- A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma, Not Recruiting
- Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma, Not Recruiting
- Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms, Not Recruiting
- Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma, Not Recruiting
- CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas, Not Recruiting
- Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma, Not Recruiting
- Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma, Not Recruiting
- Enrichment & Purging of Stem Cells in Non-Hodgkin's Lymphoma, Not Recruiting
- Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease, Not Recruiting
- High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma, Not Recruiting
- Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL, Not Recruiting
- Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT, Not Recruiting
- Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma, Not Recruiting
- Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma, Not Recruiting
- Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma, Not Recruiting
- Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma, Not Recruiting
- Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects, Not Recruiting
- Vaccine Therapy and GM-CSF in Treating Patients With Progressive Non-Hodgkin's Lymphoma, Not Recruiting

## Publications

---

### PUBLICATIONS

- **A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402** *BRITISH JOURNAL OF HAEMATOLOGY*  
Witzig, T. E., Hong, F., Micallef, I. N., Gascoyne, R. D., Dogan, A., Wagner, H., Kahl, B. S., Advani, R. H., Horning, S. J.  
2015; 170 (5): 679-686
- **Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404)** *BRITISH JOURNAL OF HAEMATOLOGY*  
Swinnen, L. J., Li, H., Quon, A., Gascoyne, R., Hong, F., Ranheim, E. A., Habermann, T. M., Kahl, B. S., Horning, S. J., Advani, R. H.  
2015; 170 (1): 56-65
- **Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial.** *Journal of clinical oncology*  
Advani, R. H., Hong, F., Fisher, R. I., Bartlett, N. L., Robinson, K. S., Gascoyne, R. D., Wagner, H., Stiff, P. J., Cheson, B. D., Stewart, D. A., Gordon, L. I., Kahl, B. S., Friedberg, et al  
2015; 33 (17): 1936-1942
- **Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial** *JOURNAL OF CLINICAL ONCOLOGY*  
Advani, R. H., Hong, F., Fisher, R. I., Bartlett, N. L., Robinson, K. S., Gascoyne, R. D., Wagner, H., Stiff, P. J., Cheson, B. D., Stewart, D. A., Gordon, L. I., Kahl, B. S., Friedberg, et al  
2015; 33 (17): 1936-U111
- **Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT).** *Journal of clinical oncology*

- Wagner, L. I., Zhao, F., Hong, F., Williams, M. E., Gascoyne, R. D., Krauss, J. C., Advani, R. H., Go, R. S., Habermann, T. M., Leach, J. W., O'Connor, B., Schuster, S. J., Cella, et al  
2015; 33 (7): 740-748
- **Anxiety and Health-Related Quality of Life Among Patients With Low-Tumor Burden Non-Hodgkin Lymphoma Randomly Assigned to Two Different Rituximab Dosing Regimens: Results From ECOG Trial E4402 (RESORT)** *JOURNAL OF CLINICAL ONCOLOGY*  
Wagner, L. I., Zhao, F., Hong, F., Williams, M. E., Gascoyne, R. D., Krauss, J. C., Advani, R. H., Go, R. S., Habermann, T. M., Leach, J. W., O'Connor, B., Schuster, S. J., Cella, et al  
2015; 33 (7)
  - **Rituximab Extended Schedule or Re-Treatment Trial for Low-Tumor Burden Follicular Lymphoma: Eastern Cooperative Oncology Group Protocol E4402** *JOURNAL OF CLINICAL ONCOLOGY*  
Kahl, B. S., Hong, F., Williams, M. E., Gascoyne, R. D., Wagner, L. I., Krauss, J. C., Habermann, T. M., Swinnen, L. J., Schuster, S. J., Peterson, C. G., Sborov, M. D., Martin, S. E., Weiss, et al  
2014; 32 (28): 3096-?
  - **Bevacizumab and cyclophosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404).** *Leukemia & lymphoma*  
Ganjoo, K., Hong, F., Horning, S. J., Gascoyne, R. D., Natkunam, Y., Swinnen, L. J., Habermann, T. M., Kahl, B. S., Advani, R. H.  
2014; 55 (4): 768-772
  - **Bevacizumab and cyclophosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404).** *Leukemia & lymphoma*  
Ganjoo, K., Hong, F., Horning, S. J., Gascoyne, R. D., Natkunam, Y., Swinnen, L. J., Habermann, T. M., Kahl, B. S., Advani, R. H.  
2014; 55 (4): 768-772
  - **Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma.** *Journal of clinical oncology*  
Advani, R. H., Horning, S. J., Hoppe, R. T., Daadi, S., Allen, J., Natkunam, Y., Bartlett, N. L.  
2014; 32 (9): 912-918
  - **Mature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyte-Predominant Hodgkin Lymphoma.** *Journal of clinical oncology*  
Advani, R. H., Horning, S. J., Hoppe, R. T., Daadi, S., Allen, J., Natkunam, Y., Bartlett, N. L.  
2014; 32 (9): 912-918
  - **Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405).** *Blood*  
Chang, J. E., Li, H., Smith, M. R., Gascoyne, R. D., Palletta, E. M., Yang, D. T., Advani, R. H., Horning, S. J., Kahl, B. S.  
2014; 123 (11): 1665-1673
  - **The role of body mass index in survival outcome for lymphoma patients: US intergroup experience** *ANNALS OF ONCOLOGY*  
Hong, F., Habermann, T. M., Gordon, L. I., Hochster, H., Gascoyne, R. D., Morrison, V. A., Fisher, R. I., Bartlett, N. L., Stiff, P. J., Cheson, B. D., Crump, M., Horning, S. J., Kahl, et al  
2014; 25 (3): 669-674
  - **An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma** *ANNALS OF ONCOLOGY*  
Hay, A. E., Klimm, B., Chen, B. E., Goergen, H., Shepherd, L. E., Fuchs, M., Gospodarowicz, M. K., Borchmann, P., Connors, J. M., Markova, J., Crump, M., Lohri, A., Winter, et al  
2013; 24 (12): 3065-3069
  - **Developing Standards for Breakthrough Therapy Designation in Oncology** *CLINICAL CANCER RESEARCH*  
Horning, S. J., Haber, D. A., Selig, W. K., Ivy, S. P., Roberts, S. A., Allen, J. D., Sigal, E. V., Sawyers, C. L.  
2013; 19 (16): 4297-4304
  - **Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience.** *Blood*  
Tan, D., Horning, S. J., Hoppe, R. T., Levy, R., Rosenberg, S. A., Sigal, B. M., Warnke, R. A., Natkunam, Y., Han, S. S., Yuen, A., Plevritis, S. K., Advani, R. H.  
2013; 122 (6): 981-987
  - **A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404)** *JOURNAL OF HEMATOLOGY & ONCOLOGY*  
Greenwald, D. R., Li, H., Luger, S. M., Go, R. S., King, D., Patel, T., Gascoyne, R. D., Kolesar, J., Kahl, B. S., Horning, S.

2013; 6

- **Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial.** *Blood*  
Kanakry, J. A., Li, H., Gellert, L. L., Lemas, M. V., Hsieh, W., Hong, F., Tan, K. L., Gascoyne, R. D., Gordon, L. I., Fisher, R. I., Bartlett, N. L., Stiff, P., Cheson, et al  
2013; 121 (18): 3547-3553
- **Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial** *ANNALS OF ONCOLOGY*  
Advani, R. H., Hoppe, R. T., Baer, D., Mason, J., Warnke, R., Allen, J., Daadi, S., Rosenberg, S. A., Horning, S. J.  
2013; 24 (4): 1044-1048
- **The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496** *BRITISH JOURNAL OF HAEMATOLOGY*  
Evens, A. M., Hong, F., Gordon, L. I., Fisher, R. I., Bartlett, N. L., Connors, J. M., Gascoyne, R. D., Wagner, H., Gospodarowicz, M., Cheson, B. D., Stiff, P. J., Advani, R., Miller, et al  
2013; 161 (1): 76-86
- **Gene Expression-Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma** *JOURNAL OF CLINICAL ONCOLOGY*  
Scott, D. W., Chan, F. C., Hong, F., Rogic, S., Tan, K. L., Meissner, B., Ben-Neriah, S., Boyle, M., Kridel, R., Telenius, A., Woolcock, B. W., Farinha, P., Fisher, et al  
2013; 31 (6): 692-700
- **Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496)** *JOURNAL OF CLINICAL ONCOLOGY*  
Gordon, L. I., Hong, F., Fisher, R. I., Bartlett, N. L., Connors, J. M., Gascoyne, R. D., Wagner, H., Stiff, P. J., Cheson, B. D., Gospodarowicz, M., Advani, R., Kahl, B. S., Friedberg, et al  
2013; 31 (6): 684-691
- **Risk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma: The Stanford University Experience Over Three Generations of Clinical Trials** *JOURNAL OF CLINICAL ONCOLOGY*  
Koontz, M. Z., Horning, S. J., Balise, R., Greenberg, P. L., Rosenberg, S. A., Hoppe, R. T., Advani, R. H.  
2013; 31 (5): 592-598
- **Second Cancers After Treatment with Stanford V Regimen in Eastern Cooperative Oncology Group (ECOG) Pilot Study E1492 At a Median Follow up of 17 Years** *54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*  
Advani, R. H., Li, H., Hoppe, R. T., Bartlett, N. L., Bennett, J. M., Neuberg, D. S., Cassileth, P. A., Kahl, B. S., Horning, S. J.  
AMER SOC HEMATOLOGY.2012
- **Mature Results From ECOG Study E1405-A Phase II Study of VcR-CVAD with Maintenance Rituximab for Previously Untreated Mantle Cell Lymphoma** *54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*  
Kahl, B. S., Li, H., Smith, M. R., Gascoyne, R. D., Yang, D. T., Paietta, E., Advani, R. H., Horning, S. J.  
AMER SOC HEMATOLOGY.2012
- **Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant** *54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*  
Karuturi, M. S., Arai, S., Chen, R. W., Gopal, A. K., Feng, L., Yuan, Y., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., Ramchandren, R., Bartlett, N. L., Cheson, et al  
AMER SOC HEMATOLOGY.2012
- **Long-term outcomes after high dose therapy and autologous haematopoietic cell rescue for refractory/relapsed Hodgkin lymphoma** *BRITISH JOURNAL OF HAEMATOLOGY*  
Minn, A. Y., Riedel, E., Halpern, J., Johnston, L. J., Horning, S. J., Hoppe, R. T., Goodman, K. A.  
2012; 159 (3): 329-339
- **Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial** *BLOOD*  
Tan, K. L., Scott, D. W., Hong, F., Kahl, B. S., Fisher, R. I., Bartlett, N. L., Advani, R. H., Buckstein, R., Rimsza, L. M., Connors, J. M., Steidl, C., Gordon, L. I., Horning, et al  
2012; 120 (16): 3280-3287

- **Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90-Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499** *JOURNAL OF CLINICAL ONCOLOGY*  
Smith, M. R., Li, H., Gordon, L., Gascoyne, R. D., Pasetta, E., Forero-Torres, A., Kahl, B. S., Advani, R., Hong, F., Horning, S. J.  
2012; 30 (25): 3119-3126
- **Activity of topotecan 21-day infusion in patients with previously treated large cell lymphoma: long-term follow-up of an Eastern Cooperative Oncology Group study (E5493)** *LEUKEMIA & LYMPHOMA*  
Wiernik, P. H., Li, H., Weller, E., Hochster, H. S., Horning, S. J., Nazeer, T., Gordon, L. I., Habermann, T. M., Minniti, C. J., Shapiro, G. R., Cassileth, P. A.  
2012; 53 (6): 1137-1142
- **Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial** *LEUKEMIA & LYMPHOMA*  
Advani, R. H., Hong, F., Horning, S. J., Kahl, B. S., Manola, J., Swinnen, L. J., Habermann, T. M., Ganjoo, K.  
2012; 53 (4): 718-720
- **ABVD Alone versus Radiation-Based Therapy in Limited-Stage Hodgkin's Lymphoma** *NEW ENGLAND JOURNAL OF MEDICINE*  
Meyer, R. M., Gospodarowicz, M. K., Connors, J. M., Pearcey, R. G., Wells, W. A., Winter, J. N., Horning, S. J., Dar, A. R., Shustik, C., Stewart, D. A., Crump, M., Djurfeldt, M. S., Chen, et al  
2012; 366 (5): 399-408
- **Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin's disease** *RADIATION ONCOLOGY*  
Tseng, D., Rachakonda, L. P., Su, Z., Advani, R., Horning, S., Hoppe, R. T., Quon, A., Graves, E. E., Loo, B. W., Tran, P. T.  
2012; 7
- **STAGE I-III A NON-BULKY HODGKIN'S LYMPHOMA. IS FURTHER DISTINCTION BASED ON PROGNOSTIC FACTORS USEFUL? THE STANFORD EXPERIENCE** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*  
Advani, R. H., Hoppe, R. T., Maeda, L. S., Baer, D. M., Mason, J., Rosenberg, S. A., Horning, S. J.  
2011; 81 (5): 1374-1379
- **Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD plus Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496** *53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*  
Advani, R., Hong, F., Gordon, L. I., Gascoyne, R. D., Wagner, H., Hoppe, R. T., Fisher, R. I., Bartlett, N. L., Kahl, B. S., Stiff, P., Cheson, B. D., Belch, A. R., Friedberg, et al  
AMER SOC HEMATOLOGY.2011: 696-97
- **Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium** *BLOOD*  
Salles, G., De Jong, D., Xie, W., Rosenwald, A., Chhanabhai, M., Gaulard, P., Klapper, W., Calaminici, M., Sander, B., Thorns, C., Campo, E., Molina, T., Lee, et al  
2011; 117 (26): 7070-7078
- **PHASE II STUDY OF R-CHOP FOLLOWED BY Y-90-IBRITUMOMAB TIUXETAN IN UNTREATED MANTLE CELL LYMPHOMA (MCL): 5 YEAR FOLLOW-UP OF EASTERN COOPERATIVE ONCOLOGY GROUP E1499** *11th International Conference on Malignant Lymphoma*  
Smith, M. R., Li, H., Gordon, L., Gascoyne, R., Pasetta, E., Forero-Torres, A., Kahl, B., Advani, R., Hong, F., Horning, S.  
OXFORD UNIV PRESS.2011: 86-87
- **Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI)** *48th Annual Meeting of the American-Society-of-Hematology*  
Advani, R. H., Chen, H., Habermann, T. M., Morrison, V. A., Weller, E. A., Fisher, R. I., Peterson, B. A., Gascoyne, R. D., Horning, S. J.  
WILEY-BLACKWELL PUBLISHING, INC.2010: 143-51
- **Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*  
Arai, S., Letsinger, R., Wong, R. M., Johnston, L. J., Laport, G. G., Lowsky, R., Miklos, D. B., Shizuru, J. A., Weng, W., Lavori, P. W., Blume, K. G., Negrin, R. S., Horning, et al  
2010; 16 (8): 1145-1154
- **Utility of Influenza Vaccination for Oncology Patients** *JOURNAL OF CLINICAL ONCOLOGY*  
Pollyea, D. A., Brown, J. M., Horning, S. J.

2010; 28 (14): 2481-2490

- **Expression of p21 Protein Predicts Clinical Outcome in DLBCL Patients Older than 60 Years Treated with R-CHOP but not CHOP: A Prospective ECOG and Southwest Oncology Group Correlative Study on E4494** *CLINICAL CANCER RESEARCH*  
Winter, J. N., Li, S., Aurora, V., Variakojis, D., Nelson, B., Krajewska, M., Zhang, L., Habermann, T. M., Fisher, R. I., Macon, W. R., Chhanabhai, M., Felgar, R. E., Hsi, et al  
2010; 16 (8): 2435-2442
- **Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study** *BLOOD*  
Horning, S. J., Juweid, M. E., Schoeder, H., Wiseman, G., McMillan, A., Swinnen, L. J., Advani, R., Gascoyne, R., Quon, A.  
2010; 115 (4): 775-777
- **Immunoglobulin G Fc Receptor Fc gamma RIIIa 158 V/F Polymorphism Correlates With Rituximab-Induced Neutropenia After Autologous Transplantation in Patients With Non-Hodgkin's Lymphoma** *JOURNAL OF CLINICAL ONCOLOGY*  
Weng, W., Negrin, R. S., Lavori, P., Horning, S. J.  
2010; 28 (2): 279-284
- **Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP)** *BRITISH JOURNAL OF HAEMATOLOGY*  
Gratzinger, D., Advani, R., Zhao, S., Talreja, N., Tibshirani, R. J., Shyam, R., Horning, S., Sehn, L. H., Farinha, P., Briones, J., Lossos, I. S., Gascoyne, R. D., Natkunam, et al  
2010; 148 (2): 235-244
- **Mid-treatment Metabolic Tumor Volume Predicts Progression and Death among Patients with Hodgkin's Disease** *52nd Annual Meeting of the American-Society-for-Therapeutic-Radiation-Oncology (ASTRO)*  
Tseng, D., Rachakonda, L. P., Su, Z., Advani, R., Horning, S., Rosenberg, S. A., Hoppe, R. T., Quon, A., Graves, E. E., Loo, B. W., Tran, P. T.  
ELSEVIER SCIENCE INC.2010: S546-S547
- **The VcR-CVAD Regimen Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma (MCL): First Analysis of E1405-A Phase II Study of VcR-CVAD with Maintenance Rituximab for MCL.** *51st Annual Meeting and Exposition of the American-Society-of-Hematology*  
Kahl, B. S., Li, H., Smith, M. R., Gascoyne, R. D., Paietta, E., Advani, R., Horning, S. J.  
AMER SOC HEMATOLOGY.2009: 663-63
- **Role of FDG-PET/CT Surveillance for Patients with Classical Hodgkin's Disease in First Complete Response: The Stanford University Experience.** *51st Annual Meeting and Exposition of the American-Society-of-Hematology*  
Maeda, L. S., Horning, S. J., Jagaru, A. H., Lin, F. I., Hoppe, R. T., Rosenberg, S. A., Advani, R. H.  
AMER SOC HEMATOLOGY.2009: 626-26
- **Efficacy of Abbreviated Stanford V Chemotherapy and Involved Field Radiotherapy in Early Stage Hodgkin's Disease: Mature Results of the G4 Trial.** *51st Annual Meeting and Exposition of the American-Society-of-Hematology*  
Advani, R. H., Hoppe, R. T., Baer, D. M., Mason, J., Rosenberg, S. A., Horning, S. J.  
AMER SOC HEMATOLOGY.2009: 666-67
- **Cancer Research and Privacy: The Problem With Being Joined at the Hip** *JOURNAL OF CLINICAL ONCOLOGY*  
Horning, S. J.  
2009; 27 (24): 3879-3880
- **Prognostic significance of vascular endothelial growth factor (VEGF), VEGF receptors (VEGFR), and vascularity in diffuse large B-cell lymphoma treated with immunochemotherapy (R-CHOP)** *45th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*  
Gratzinger, D., Advani, R., Zhao, S., Talreja, N., Tibshirani, R. J., Horning, S. J., Levy, R., Lossos, I. S., Gascoyne, R. D., Natkunam, Y.  
AMER SOC CLINICAL ONCOLOGY.2009
- **Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus (EBV) antigens in patients with EBV-negative Hodgkin's disease** *45th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*  
Kohrt, H. E., Advani, R., Hoppe, R., Rosenberg, S., Horning, S., Lee, P. P.  
AMER SOC CLINICAL ONCOLOGY.2009
- **Low Stage Follicular Lymphoma: Biologic and Clinical Characterization According to Nodal or Extranodal Primary Origin** *AMERICAN JOURNAL OF SURGICAL PATHOLOGY*  
Weinberg, O. K., Ma, L., Seo, K., Beck, A. H., Pai, R. K., Morales, A., Kim, Y., Sundram, U., Tan, D., Horning, S. J., Hoppe, R. T., Natkunam, Y., Arber, et al  
2009; 33 (4): 591-598

- **Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study** *48th Annual Meeting of the American-Society-of-Hematology*  
Hochster, H., Weller, E., Gascoyne, R. D., Habermann, T. M., Gordon, L. I., Ryan, T., Zhang, L., Colocci, N., Frankel, S., Horning, S. J.  
AMER SOC CLINICAL ONCOLOGY.2009: 1607-14
- **Dynamic CD8 T-Cell Responses to Tumor-Associated Epstein-Barr Virus Antigens in Patients With Epstein-Barr Virus-Negative Hodgkin's Disease** *ONCOLOGY RESEARCH*  
Kohrt, H., Johannsen, A., Hoppe, R., Horning, S. J., Rosenberg, S. A., Advani, R., Lee, P. P.  
2009; 18 (5-6): 287-292
- **LMO2 Protein Expression Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy (RCHOP): A Multicenter Validation Study.** *50th Annual Meeting of the American-Society-of-Hematology/ASH/ASCO Joint Symposium*  
Advani, R., Talreja, N., Tibshirani, R., Zhao, S., Alizadeh, A., Briones, J., Bordes, R., Cohen, J., Horning, S., Levy, R., Lossos, I. S., Natkunam, Y.  
AMER SOC HEMATOLOGY.2008: 1291-91
- **Phase I/II Trial of a Novel Gemcitabine and Vinorelbine-Containing Conditioning Regimen in Autologous Hematopoietic Cell Transplantation for High-Risk Recurrent and Refractory Hodgkin Lymphoma.** *50th Annual Meeting of the American-Society-of-Hematology/ASH/ASCO Joint Symposium*  
Arai, S., Letsinger, R., Johnston, L., Laport, G., Lowsky, R., Miklos, D., Shizuru, J., Weng, W., Wong, R., Lavori, P., Blume, K., Negrin, R., Horning, et al  
AMER SOC HEMATOLOGY.2008: 765-66
- **Follicular lymphoma, survival, and rituximab: Is it time to declare victory?** *JOURNAL OF CLINICAL ONCOLOGY*  
Horning, S. J.  
2008; 26 (28): 4537-4538
- **Follicular Lymphoma: Clinical Features and Treatment** *HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA*  
Tan, D., Horning, S. J.  
2008; 22 (5): 863-?
- **F-18-FDG-PET/CT evaluation of response to treatment in lymphoma: when is the optimal time for the first re-evaluation scan?** *HELLENIC JOURNAL OF NUCLEAR MEDICINE*  
Iagaru, A., Wang, Y., Mari, C., Quon, A., Goris, M. L., Horning, S., Gambhir, S. S.  
2008; 11 (3): 153-156
- **Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: The Stanford experience** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*  
Chen, A. I., McMillan, A., Neprin, R. S., Horning, S. J., Laport, G. G.  
2008; 14 (7): 741-747
- **Clinical and immunologic responses to a novel in situ lymphoma vaccine maneuver: Results of a phase II trial of intra-tumoral CPG-[PF-3512676]** *10th International Conference on Malignant Lymphoma*  
Brody, J. D., Ai, W. Z., Czerwinski, D. K., Advani, R., Horning, S. J., Hoppe, R. T., Levy, R.  
OXFORD UNIV PRESS.2008: 158-158
- **Improved prognosis after histologic transformation (HT) of follicular lymphoma (FL): The Stanford experience 1960-2003** *10th International Conference on Malignant Lymphoma*  
Tan, D., Rosenberg, S. A., Lavori, P., Levy, R., Hoppe, R., Warnke, R., Advani, R., Natkunam, Y., Yuen, A., Horning, S. J.  
OXFORD UNIV PRESS.2008: 111-112
- **Attitudes and beliefs towards survivorship issues in Hodgkin's disease (HD). Results of focus group discussions with patients treated at stanford university** *10th International Conference on Malignant Lymphoma*  
Advani, R., Rosenberg, S., Talreja, N., Hoppe, R., Horning, S.  
OXFORD UNIV PRESS.2008: 137-137
- **Clinical and immunologic responses to a novel in situ lymphoma vaccine maneuver: Preliminary results of a phase II trial of intra-tumoral CpG 7909**  
Brody, J., Ai, W. Z., Czerwinski, D., Advani, R., Horning, S. J., Ganjoo, K. N., Levy, R.  
AMER SOC CLINICAL ONCOLOGY.2008
- **Closing the gap: A comparison of observed versus expected survival in follicular lymphoma (FL) at Stanford University from 1960-2003**  
Tan, D., Rosenberg, S. A., Lavori, P., Sigal, B. M., Levy, R., Hoppe, R. T., Warnke, R., Advani, R., Natkunam, Y., Plevritis, S. K., Horning, S. J.  
AMER SOC CLINICAL ONCOLOGY.2008

- **Follow-up of adult cancer survivors: New paradigms for survivorship care planning** *HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA*  
Horning, S. J.  
2008; 22 (2): 201-?
- **Autologous cytokine-induced killer cells as post-transplant cellular immunotherapy** *49th Annual Meeting of the American-Society-of-Hematology*  
Arai, S., Sheehan, K., Moore, S., Laport, G., Johnston, L., Lowsky, R., Miklos, D., Goldstein, K., Weng, W., Shizuru, J., Horning, S., Negrin, R.  
AMER SOC HEMATOLOGY.2007: 179A-179A
- **Stage I/II Hodgkin's disease: Comparison of outcomes of patients with bulky mediastinal disease versus other risk factors; the Stanford V experience**  
Advani, R. H., Hoppe, R. T., Rosenberg, S. A., Horning, S. J.  
AMER SOC HEMATOLOGY.2007: 685A-685A
- **Phase II study of R-CHOP followed by Y-90-ibritumomab tiuxetan in untreated mantle cell lymphoma: Eastern cooperative oncology group study E1499** *49th Annual Meeting of the American-Society-of-Hematology*  
Smith, M. R., Zhang, L., Gordon, L. I., Foran, J., Kahl, B., Gascoyne, R. D., Advani, R., Paietta, E., Weller, E., Horning, S. J.  
AMER SOC HEMATOLOGY.2007: 121A-121A
- **Survival in follicular lymphoma: The Stanford experience, 1960-2003.** *49th Annual Meeting of the American-Society-of-Hematology*  
Tan, D., Rosenberg, S. A., Levy, R., Lavori, P., Tibshirani, R., Hoppe, R. T., Warnke, R., Advani, R., Natkunam, Y., Yuen, A., Horning, S. J.  
AMER SOC HEMATOLOGY.2007: 1005A-1005A
- **Stage I/II Hodgkin's disease (HD) with bulky mediastinal disease or other risk factors (RF) the Stanford V experience** *7th International Symposium on Hodgkins Lymphoma*  
Advani, R. H., Hoppe, R. T., Rosenberg, S. A., Horning, S. J.  
FERRATA STORTI FOUNDATION.2007: 27-27
- **A prospective trial of involved field radiation (IFRT) plus chemotherapy vs extended field (EFRT) radiation for favorable Hodgkin's disease (HD): Long-term follow-up and implications for current combined modality therapy** *7th International Symposium on Hodgkins Lymphoma*  
Horning, S. J., Hoppe, R. T., Advani, R. H., Breslin, S., McCormick, E., Allen, J., Hancock, S. L., Rosenberg, S. A.  
FERRATA STORTI FOUNDATION.2007: 53-53
- **Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with limited-stage Hodgkin lymphoma** *ANNALS OF ONCOLOGY*  
MacDonald, D. A., Ding, K., Gospodarowicz, M. K., Wells, W. A., Pearcey, R. G., Connors, J. M., Winter, J. N., Horning, S. J., Djurfeldt, M. S., Shepherd, L. E., Meyer, R. M.  
2007; 18 (10): 1680-1684
- **Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease** *9th International Conference on Malignant Lymphoma*  
Advani, R., Maeda, L., Lavori, P., Quon, A., Hoppe, R., Breslin, S., Rosenberg, S. A., Horning, S. J.  
AMER SOC CLINICAL ONCOLOGY.2007: 3902-7
- **Non-Hodgkin lymphoma of the breast** *CANCER*  
Ganjoo, K., Advani, R., Mariappan, M. R., McMillan, A., Horning, S.  
2007; 110 (1): 25-30
- **FDG-PET lymphoma demonstration project invitational workshop** *ACADEMIC RADIOLOGY*  
Kelloff, G. J., Sullivan, D. M., Wilson, W., Cheson, B., Juweid, M., Mills, G. Q., Zelenetz, A. D., Horning, S. J., Weber, W., Sargent, D. J., Dodd, L., Korn, E., Armitage, et al  
2007; 14 (3): 330-339
- **Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: Validation of tissue microarray as a prerequisite for broad clinical applications - A study from the Lunenburg Lymphoma Biomarker Consortium** *JOURNAL OF CLINICAL ONCOLOGY*  
de Jong, D., Rosenwald, A., Chhanabhai, M., Gaulard, P., Klapper, W., Lee, A., Sander, B., Thorns, C., Campo, E., Molina, T., Norton, A., Hagenbeek, A., Horning, et al  
2007; 25 (7): 805-812
- **Revised response criteria for malignant lymphoma** *JOURNAL OF CLINICAL ONCOLOGY*  
Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., Rosen, S. T., Stroobants, S., Lister, et al  
2007; 25 (5): 579-586



- **Angioimmunoblastic T cell lymphoma: Treatment experience with cyclosporine** *LEUKEMIA & LYMPHOMA*  
Advani, R., Horwitz, S., Zelenetz, A., Horning, S. J.  
2007; 48 (3): 521-525
- **Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: Final results of E1497** *LEUKEMIA & LYMPHOMA*  
Kuzel, T. M., Li, S., Eklund, J., Foss, F., Gascoyne, R., Abramson, N., Schwerkoske, J. F., Weller, E., Horning, S. J.  
2007; 48 (12): 2397-2402
- **Risk, cure and complications in advanced hodgkin disease.** *Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program*  
Horning, S. J.  
2007: 197-203
- **Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease** *JOURNAL OF CLINICAL ONCOLOGY*  
Heidenreich, P. A., Schnittger, I., Strauss, H. W., Vagelos, R. H., Lee, B. K., Mariscal, C. S., Tate, D. J., Horning, S. J., Hoppe, R. T., Hancock, S. L.  
2007; 25 (1): 43-49
- **High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*  
Law, L. Y., Horning, S. J., Wong, R. M., Johnston, L. J., Laport, G. G., Lowsky, R., Shizuru, J. A., Blume, K. G., Negrin, R. S., Stockerl-Goldstein, K. E.  
2006; 12 (7): 703-711
- **Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma** *JOURNAL OF CLINICAL ONCOLOGY*  
Habermann, T. M., Weller, E. A., Morrison, V. A., Gascoyne, R. D., Cassileth, P. A., Cohn, J. B., Dakhil, S. R., Woda, B., Fisher, R. I., Peterson, B. A., Horning, S. J.  
2006; 24 (19): 3121-3127
- **Incidence of secondary leukemia/myelodysplasia (AML/MDS) in Hodgkin's disease (HD) with three generations of therapy at Stanford University.** *42nd Annual Meeting of the American-Society-of-Clinical-Oncology*  
Advani, R. H., Hoppe, R. T., Rosenberg, S. A., Horning, S. J.  
AMER SOC CLINICAL ONCOLOGY.2006: 426S-426S
- **Rituximab, Bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis** *LEUKEMIA & LYMPHOMA*  
Ganjoo, K. N., An, C. S., Robertson, M. J., Gordon, L. I., Sen, J. A., Weisenbach, J., Li, S., Weller, E. A., Orazi, A., Horning, S. J.  
2006; 47 (6): 998-1005
- **Management of advanced stage Hodgkin lymphoma.** *Journal of the National Comprehensive Cancer Network*  
Advani, R., Ai, W. Z., Horning, S. J.  
2006; 4 (3): 241-247
- **Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group** *45th Annual Meeting and Exhibition of the American-Society-of-Hematology*  
Meyer, R. M., Gospodarowicz, M. K., Connors, J. M., Pearcey, R. G., Bezjak, A., Wells, W. A., Burns, B. E., Winter, J. N., Horning, S. J., Dar, A. R., Djurfeldt, M. S., Ding, K., Shepherd, et al  
AMER SOC CLINICAL ONCOLOGY.2005: 4634-42
- **Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-Cell lymphoma, progressive after rituximab** *42nd Annual Meeting of the American-Society-of-Hematology*  
Horning, S. J., Younes, A., Jain, V., KROLL, S., Lucas, J., Podoloff, D., Goris, M.  
AMER SOC CLINICAL ONCOLOGY.2005: 712-19
- **Clinical and pathological features of posttransplantation lymphoproliferative disorders presenting with skin involvement in 4 patients** *ARCHIVES OF DERMATOLOGY*  
Beynet, D. P., Wee, S. A., Horwitz, S. S., Kohler, S., Horning, S., Hoppe, R., Kim, Y. H.  
2004; 140 (9): 1140-1146
- **Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern cooperative oncology group study 1484** *43rd Annual Meeting of the American-Society-of-Hematology*

- Horning, S. J., Weller, E., Kim, K. M., Earle, J. D., O'Connell, M. J., Habermann, T. M., Glick, J. H.  
AMER SOC CLINICAL ONCOLOGY.2004: 3032-38
- **Rituximab in stem cell transplantation for aggressive lymphoma.** *Current hematology reports*  
Horwitz, S. M., Horning, S. J.  
2004; 3 (4): 227-229
  - **Stage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy** *8th International Conference on Malignant Lymphoma*  
Advani, R., Rosenberg, S. A., Horning, S. J.  
AMER SOC CLINICAL ONCOLOGY.2004: 1454-59
  - **Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma** *43rd Annual Meeting of the American-Society-of-Hematology*  
Horwitz, S. M., Negrin, R. S., Blume, K. G., Breslin, S., Stuart, M. J., Stockerl-Goldstein, K. E., JOHNSTON, L. J., Wong, R. M., Shizuru, J. A., Horning, S. J.  
AMER SOC HEMATOLOGY.2004: 777-83
  - **Future directions in radioimmunotherapy for B-cell lymphoma** *SEMINARS IN ONCOLOGY*  
Horning, S. J.  
2003; 30 (6): 29-34
  - **Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial** *BLOOD*  
Ekstrand, B. C., Lucas, J. B., Horwitz, S. M., Fan, Z., Breslin, S., Hoppe, R. T., Natkunam, Y., Bartlett, N. L., Horning, S. J.  
2003; 101 (11): 4285-4289
  - **Lymphocyte predominant Hodgkin's disease: More patience than patients** *CANCER JOURNAL*  
Ekstrand, B. C., Horning, S. J.  
2002; 8 (5): 367-368
  - **Lymphocyte predominant Hodgkin's disease.** *Current oncology reports*  
Ekstrand, B. C., Horning, S. J.  
2002; 4 (5): 424-433
  - **Hodgkin's disease** *BLOOD REVIEWS*  
Ekstrand, B. C., Horning, S. J.  
2002; 16 (2): 111-117
  - **Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: Mature results of a prospective clinical trial** *JOURNAL OF CLINICAL ONCOLOGY*  
Horning, S. J., Hoppe, R. T., Breslin, S., Bartlett, N. L., Brown, B. W., Rosenberg, S. A.  
2002; 20 (3): 630-637
  - **Durable remission in recurrent T-cell-rich B-cell lymphoma with the anti-CD20 antibody rituximab** *CLINICAL LYMPHOMA*  
Natkunam, Y., Stanton, T. S., Warnke, R. A., Horning, S. J.  
2001; 2 (3): 185-187
  - **High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial** *BLOOD*  
Horning, S. J., Negrin, R. S., Hoppe, R. T., Rosenberg, S. A., Chao, N. J., Long, G. D., Brown, B. W., Blume, K. G.  
2001; 97 (2): 404-409
  - **Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*  
Stuart, M. J., Chao, N. S., Horning, S. J., Wong, R. M., Negrin, R. S., JOHNSTON, L. J., Shizuru, J. A., Long, G. D., Blume, K. G., Stockerl-Goldstein, K. E., Goldstein, S.  
2001; 7 (10): 552-560
  - **High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: The Stanford University experience** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*  
Cao, T. M., Horning, S. F., Negrin, R. S., Hu, W. W., Johnston, L. F., Taylor, T. L., Shizuru, J. A., Hoppe, R. T., Brown, B. W., Blume, K. G., Stockerl-Goldstein, K.  
2001; 7 (5): 294-301

- **Advances in the treatment of Hodgkin's lymphoma** *CURRENT OPINION IN HEMATOLOGY*  
Horwitz, S. M., Horning, S. J.  
2000; 7 (4): 235-240
- **Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group Pilot Study E1492** *JOURNAL OF CLINICAL ONCOLOGY*  
Horning, S. J., Williams, J., Bartlett, N. L., Bennett, J. M., Hoppe, R. T., Neuberger, D., Cassileth, P.  
2000; 18 (5): 972-980
- **Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*  
Johnston, L. J., Stockerl-Goldstein, K. E., Hu, W. W., Negrin, R. S., Hoppe, R. T., Blume, K. G., Horning, S. J.  
2000; 6 (5A): 555-562
- **Autologous hematopoietic cell transplantation in Hodgkin's disease** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*  
JOHNSTON, L. J., Horning, S. J.  
2000; 6 (3A): 289-300
- **High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*  
Alvarnas, J. C., Negrin, R. S., Horning, S. J., Hu, W. W., Long, G. D., Schriber, J. R., Stockerl-Goldstein, K., Tierney, K., Wong, R., Blume, K. G., Chao, N. J.  
2000; 6 (3A): 352-358
- **Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*  
Stockerl-Goldstein, K. E., Reddy, S. A., Horning, S. J., Blume, K. G., Chao, N. J., Hu, W. W., JOHNSTON, L. J., Long, G. D., Strober, S., Wong, R. M., Feiner, R. H., Kohler, S., Negrin, et al  
2000; 6 (5): 506-512
- **Follicular lymphoma: Have we made any progress?** *International Conference on Malignant Lymphoma*  
Horning, S. J.  
OXFORD UNIV PRESS.2000: 23-27
- **Autologous hematopoietic cell transplantation in non-Hodgkin's lymphoma** *HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA*  
Johnston, L. J., Horning, S. J.  
1999; 13 (5): 889-?
- **Treatment of early-stage Hodgkin's disease** *SEMINARS IN HEMATOLOGY*  
Advani, R. H., Horning, S. J.  
1999; 36 (3): 270-281
- **Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas** *JOURNAL OF CLINICAL ONCOLOGY*  
Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippenstein, D., Hiddemann, et al  
1999; 17 (4): 1244-1253
- **Advances in the management of Hodgkin's and non-Hodgkin's lymphoma.** *Current opinion in hematology*  
Davis, T. A., Horning, S. J.  
1998; 5 (4): 259-263
- **A prognostic score for advanced Hodgkin's disease.** *New England Journal of Medicine*  
Hasenclever D, Diehl V, Armitage JO, Assouline D, Bjorkholm M, Brusamolino E, Canellos GP, Carde P, Crowther D, Cunningham D, Eghbali H, Ferme C, Fisher RI, Glick JH, Glimelius B, Gobbi PG, Holte H, Horning SJ et al.  
1998; 229 (21): 1506-14
- **Primary refractory Hodgkin's disease.** *Annals of oncology*  
Horning, S. J.  
1998; 9: S97-101
- **High-dose therapy and transplantation for low-grade lymphoma** *HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA*  
Horning, S. J.

- 1997; 11 (5): 919-?
- **Recent advances in the treatment of Hodgkin's disease.** *Current opinion in hematology*  
Yuen, A. R., Horning, S. J.  
1997; 4 (4): 286-290
  - **Treatment of angioimmunoblastic T-cell lymphoma with cyclosporine** *ANNALS OF ONCOLOGY*  
Advani, R., Warnke, R., Sikic, B. I., Horning, S.  
1997; 8 (6): 601-603
  - **Stanford-Kaiser permanente G1 study for clinical stage I to IIA Hodgkin's disease: Subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation** *JOURNAL OF CLINICAL ONCOLOGY*  
Horning, S. J., Hoppe, R. T., Mason, J., Brown, B. W., Hancock, S. L., Baer, D., Rosenberg, S. A.  
1997; 15 (5): 1736-1744
  - **High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices** *BLOOD*  
Horning, S. J., Chao, N. J., Negrin, R. S., Hoppe, R. T., Long, G. D., Hu, W. W., Wong, R. M., Brown, B. W., Blume, K. G.  
1997; 89 (3): 801-813
  - **Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease** *BLOOD*  
Yuen, A. R., Rosenberg, S. A., Hoppe, R. T., HALPERN, J. D., Horning, S. J.  
1997; 89 (3): 814-822
  - **Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma.** *Biology of blood and marrow transplantation*  
Stockerl-Goldstein, K. E., Horning, S. J., Negrin, R. S., Chao, N. J., Hu, W. W., Long, G. D., Hoppe, R. T., Amylon, M. D., BROWN, B. W., Wong, R. M., Blume, K. G.  
1996; 2 (2): 76-85
  - **Purine analogs in marginal-zone lymphomas.** *Annals of oncology*  
Horning, S. J.  
1996; 7: S21-6
  - **Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin's disease: An update** *3rd International Symposium on Hodgkins Lymphoma*  
Horning, S. J., Rosenberg, S. A., Hoppe, R. T.  
KLUWER ACADEMIC PUBL.1996: 105-108
  - **Recent advances in Hodgkin's disease.** *Current opinion in hematology*  
Yuen, A. R., Horning, S. J.  
1995; 2 (4): 262-267
  - **LONG-TERM SURVIVAL AFTER HISTOLOGIC TRANSFORMATION OF LOW-GRADE FOLLICULAR LYMPHOMA** *JOURNAL OF CLINICAL ONCOLOGY*  
Yuen, A. R., Kamel, O. W., Halpern, J., Horning, S. J.  
1995; 13 (7): 1726-1733
  - **TRANSPLANTATION OF ENRICHED AND PURGED PERIPHERAL-BLOOD PROGENITOR CELLS FROM A SINGLE APHERESIS PRODUCT IN PATIENTS WITH NON-HODGKINS-LYMPHOMA** *BLOOD*  
Negrin, R. S., KUSNIERZGLAZ, C. R., Still, B. J., Schriber, J. R., Chao, N. J., Long, G. D., Hoyle, C., Hu, W. W., Horning, S. J., Brown, B. W., Blume, K. G., Strober, S.  
1995; 85 (11): 3334-3341
  - **BRIEF CHEMOTHERAPY, STANFORD-V, AND ADJUVANT RADIOTHERAPY FOR BULKY OR ADVANCED-STAGE HODGKINS-DISEASE - A PRELIMINARY-REPORT** *JOURNAL OF CLINICAL ONCOLOGY*  
Bartlett, N. L., Rosenberg, S. A., Hoppe, R. T., Hancock, S. L., Horning, S. J.  
1995; 13 (5): 1080-1088
  - **A NEW PREPARATORY REGIMEN FOR AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR PATIENTS WITH LYMPHOMA** *CANCER*  
Chao, N. J., Kastrissios, H., Long, G. D., Negrin, R. S., Horning, S. J., Wong, R. M., Blaschke, T. F., Blume, K. G.

1995; 75 (6): 1354-1359

- **FRACTIONATED TOTAL-BODY IRRADIATION, ETOPOSIDE, AND CYCLOPHOSPHAMIDE PLUS AUTOGRAFTING IN HODGKINS-DISEASE AND NON-HODGKINS-LYMPHOMA** *JOURNAL OF CLINICAL ONCOLOGY*  
Horning, S. J., Negrin, R. S., Chao, N. J., Long, G. D., Hoppe, R. T., Blume, K. G.  
1994; 12 (12): 2552-2558
- **FOLLICULAR LARGE-CELL LYMPHOMA - INTERMEDIATE OR LOW-GRADE** *JOURNAL OF CLINICAL ONCOLOGY*  
Bartlett, N. L., Rizeq, M., Dorfman, R. F., Halpern, J., Horning, S. J.  
1994; 12 (7): 1349-1357
- **TREATMENT APPROACHES TO THE LOW-GRADE LYMPHOMAS** *BLOOD*  
Horning, S. J.  
1994; 83 (4): 881-884
- **EFFECT OF TREATMENT FOR HODGKINS-DISEASE ON PULMONARY-FUNCTION - RESULTS OF A PROSPECTIVE-STUDY** *JOURNAL OF CLINICAL ONCOLOGY*  
Horning, S. J., Adhikari, A., Rizk, N., Hoppe, R. T., Olshen, R. A.  
1994; 12 (2): 297-305
- **Low-grade lymphoma 1993: state of the art.** *Annals of oncology*  
Horning, S. J.  
1994; 5: 23-27
- **NATURAL-HISTORY OF AND THERAPY FOR THE INDOLENT NON-HODGKINS-LYMPHOMAS** *SEMINARS IN ONCOLOGY*  
Horning, S. J.  
1993; 20 (5): 75-88
- **THE EFFICACY OF GRANULOCYTE-COLONY-STIMULATING FACTOR FOLLOWING AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR NON-HODGKINS-LYMPHOMA WITH MONOCLONAL-ANTIBODY PURGED BONE-MARROW** *LEUKEMIA*  
Schriber, J. R., Negrin, R. S., Chao, N. J., Long, G. D., Horning, S. J., Blume, K. G.  
1993; 7 (10): 1491-1495
- **MACOP-B +/- RADIATION-THERAPY FOR DIFFUSE LARGE-CELL LYMPHOMA - ANALYSIS OF THE STANFORD RESULTS ACCORDING TO PROGNOSTIC INDEXES** *CANCER*  
Bartlett, N. L., Kwak, L. W., Horning, S. J.  
1993; 71 (12): 4034-4042
- **EPSTEIN-BARR VIRUS-ASSOCIATED LYMPHOPROLIFERATIVE DISORDER FOLLOWING AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR NON-HODGKINS-LYMPHOMA** *TRANSPLANTATION*  
Chao, N. J., Berry, G. J., Advani, R., Horning, S. J., Weiss, L. M., Blume, K. G.  
1993; 55 (6): 1425-1428
- **GRANULOCYTE COLONY-STIMULATING FACTOR MOBILIZED PERIPHERAL-BLOOD PROGENITOR CELLS ACCELERATE GRANULOCYTE AND PLATELET RECOVERY AFTER HIGH-DOSE CHEMOTHERAPY** *BLOOD*  
Chao, N. J., Schriber, J. R., Grimes, K., Long, G. D., Negrin, R. S., RAIMONDI, C. M., Horning, S. J., Brown, S. L., Miller, L., Blume, K. G.  
1993; 81 (8): 2031-2035
- **HODGKINS-DISEASE WITH BULKY MEDIASTINAL INVOLVEMENT - EFFECTIVE MANAGEMENT WITH COMBINED MODALITY THERAPY** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*  
BEHAR, R. A., Horning, S. J., Hoppe, R. T.  
1993; 25 (5): 771-776
- **THE STANFORD EXPERIENCE WITH COMBINED PROCARBAZINE, ALKERAN AND VINBLASTINE (PAVE) AND RADIOTHERAPY FOR LOCALLY EXTENSIVE AND ADVANCED STAGE HODGKINS-DISEASE** *ANNALS OF ONCOLOGY*  
Horning, S. J., Ang, P. T., Hoppe, R. T., Rosenberg, S. A.  
1992; 3 (9): 747-754
- **DYNAMIC ASSESSMENT OF QUALITY-OF-LIFE AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION** *BLOOD*  
Chao, N. J., Tierney, D. K., Bloom, J. R., Long, G. D., Barr, T. A., STALLBAUM, B. A., Wong, R. M., Negrin, R. S., Horning, S. J., Blume, K. G.  
1992; 80 (3): 825-830

- **GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) AS AN ADJUNCT TO AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION FOR LYMPHOMA** *ANNALS OF INTERNAL MEDICINE*  
Advani, R., Chao, N. J., Horning, S. J., Blume, K. G., Ahn, D. K., Lamborn, K. R., FLEMING, N. C., Bonnem, E. M., Greenberg, P. L.  
1992; 116 (3): 183-189
- **CLINICAL-SIGNIFICANCE OF MORPHOLOGICAL SUBDIVISION IN DIFFUSE LARGE CELL LYMPHOMA** *CANCER*  
Kwak, L. W., Wilson, M., Weiss, L. M., Horning, S. J., Warnke, R. A., Dorfman, R. F.  
1991; 68 (9): 1988-1993
- **MOLECULAR BIOLOGIC STUDIES IN THE CLINICAL-EVALUATION OF NON-HODGKINS-LYMPHOMA** *HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA*  
Hardy, R., Horning, S. J.  
1991; 5 (5): 891-900
- **SIMILAR OUTCOME OF TREATMENT OF B-CELL AND T-CELL DIFFUSE LARGE-CELL LYMPHOMAS - THE STANFORD EXPERIENCE** *JOURNAL OF CLINICAL ONCOLOGY*  
Kwak, L. W., Wilson, M., Weiss, L. M., DOGGETT, R., Dorfman, R. F., Warnke, R. A., Horning, S. J.  
1991; 9 (8): 1426-1431
- **THE STANFORD HODGKINS-DISEASE (HD) STUDIES - AN UPDATE** *2ND VICENZA INTERNATIONAL WORKSHOP OF HEMATOLOGY : NEW INSIGHTS IN LYMPHOMAS*  
Horning, S. J.  
STOCKTON PRESS.1991: 53-55
- **CORTICOSTEROID-THERAPY FOR DIFFUSE ALVEOLAR HEMORRHAGE IN AUTOLOGOUS BONE-MARROW TRANSPLANT RECIPIENTS** *ANNALS OF INTERNAL MEDICINE*  
Chao, N. J., Duncan, S. R., Long, G. D., Horning, S. J., Blume, K. G.  
1991; 114 (2): 145-146
- **THE STANFORD EXPERIENCE WITH HIGH-DOSE ETOPOSIDE CYTOREDUCTIVE REGIMENS AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN HODGKINS-DISEASE AND NON-HODGKINS-LYMPHOMA - PRELIMINARY DATA** *ANNALS OF ONCOLOGY*  
Horning, S. J., Chao, N. J., Negrin, R. S., Hoppe, R. T., Kwak, L. W., Long, G. D., STALLBAUM, B., OCONNOR, P., Blume, K. G.  
1991; 2: 47-50
- **CEPP(B) - AN EFFECTIVE AND WELL-TOLERATED REGIMEN IN POOR-RISK, AGGRESSIVE NON-HODGKINS-LYMPHOMA** *BLOOD*  
Chao, N. J., Rosenberg, S. A., Horning, S. J.  
1990; 76 (7): 1293-1298
- **PROGNOSTIC-SIGNIFICANCE OF ACTUAL DOSE INTENSITY IN DIFFUSE LARGE-CELL LYMPHOMA - RESULTS OF A TREE-STRUCTURED SURVIVAL ANALYSIS** *JOURNAL OF CLINICAL ONCOLOGY*  
Kwak, L. W., Halpern, J., Olshen, R. A., Horning, S. J.  
1990; 8 (6): 963-977
- **DETECTION OF NON-HODGKINS-LYMPHOMA IN THE PERIPHERAL-BLOOD BY ANALYSIS OF ANTIGEN RECEPTOR GENE REARRANGEMENTS - RESULTS OF A PROSPECTIVE-STUDY** *BLOOD*  
Horning, S. J., Galili, N., Cleary, M., Sklar, J.  
1990; 75 (5): 1139-1145
- **Bone marrow transplantation for hematologic malignancies: the Stanford experience.** *Clinical transplants*  
Chao, N. J., Amylon, M. D., Long, G. D., Negrin, R. S., Hoppe, R. T., Horning, S. J., Blume, K. G.  
1990: 157-163
- **LYMPHOMAS PRESENTING AS HISTOLOGICALLY UNCLASSIFIED NEOPLASMS - CHARACTERISTICS AND RESPONSE TO TREATMENT** *JOURNAL OF CLINICAL ONCOLOGY*  
Horning, S. J., CARRIER, E. K., Rouse, R. V., Warnke, R. A., Michie, S. A.  
1989; 7 (9): 1281-1287
- **NUMBERS OF HOST HELPER T-CELLS AND PROLIFERATING CELLS PREDICT SURVIVAL IN DIFFUSE SMALL-CELL LYMPHOMAS** *JOURNAL OF CLINICAL ONCOLOGY*  
Medeiros, L. J., Picker, L. J., Gelb, A. B., Strickler, J. G., BRAIN, S. W., Weiss, L. M., Horning, S. J., Warnke, R. A.  
1989; 7 (8): 1009-1017

- **SMALL LYMPHOCYTIC LYMPHOMA** *JOURNAL OF CLINICAL ONCOLOGY*  
Morrison, W. H., Hoppe, R. T., Weiss, L. M., Picozzi, V. J., Horning, S. J.  
1989; 7 (5): 598-606
- **TREATMENT OF B-CELL LYMPHOMAS WITH ANTI-IDIOTYPE ANTIBODIES ALONE AND IN COMBINATION WITH ALPHA INTERFERON** *BLOOD*  
Brown, S. L., MILLER, R. A., Horning, S. J., Czerwinski, D., Hart, S. M., MCELDERRY, R., BASHAM, T., Warnke, R. A., Merigan, T. C., Levy, R.  
1989; 73 (3): 651-661
- **EXPRESSION OF LFA-1 IN NON-HODGKINS LYMPHOMA** *CANCER*  
Medeiros, L. J., Weiss, L. M., Picker, L. J., CLAYBERGER, C., Horning, S. J., KRENSKY, A. M., Warnke, R. A.  
1989; 63 (2): 255-259
- **NON-HODGKIN LYMPHOMA - INFLUENCE OF LYMPHOGRAPHY, CT, AND BONE-MARROW BIOPSY ON STAGING AND MANAGEMENT** *RADIOLOGY*  
Pond, G. D., Castellino, R. A., Horning, S., Hoppe, R. T.  
1989; 170 (1): 159-164
- **Current Stanford clinical trials for Hodgkin's disease.** *Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer*  
Hoppe, R. T., Horning, S. J., Hancock, S. L., Rosenberg, S. A.  
1989; 117: 182-190
- **VINBLASTINE, BLEOMYCIN, AND METHOTREXATE - AN EFFECTIVE ADJUVANT IN FAVORABLE HODGKINS-DISEASE** *JOURNAL OF CLINICAL ONCOLOGY*  
Horning, S. J., Hoppe, R. T., Hancock, S. L., Rosenberg, S. A.  
1988; 6 (12): 1822-1831
- **COMBINED MODALITY THERAPY FOR STAGE-I-II LARGE CELL LYMPHOMA** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*  
Prestidge, B. R., Horning, S. J., Hoppe, R. T.  
1988; 15 (3): 633-639
- **COMPARISON OF HOST-CELL INFILTRATES IN PATIENTS WITH FOLLICULAR LYMPHOMA WITH AND WITHOUT SPONTANEOUS REGRESSION** *AMERICAN JOURNAL OF CLINICAL PATHOLOGY*  
Strickler, J. G., COPENHAVER, C. M., ROJAS, V. A., Horning, S. J., Warnke, R. A.  
1988; 90 (3): 257-261
- **INTERCURRENT DEATH AFTER HODGKIN DISEASE THERAPY IN RADIOTHERAPY AND ADJUVANT MOPP TRIALS** *ANNALS OF INTERNAL MEDICINE*  
Hancock, S. L., Hoppe, R. T., Horning, S. J., Rosenberg, S. A.  
1988; 109 (3): 183-189
- **TRANSFERRIN RECEPTOR EXPRESSION BY NON-HODGKINS LYMPHOMAS - CORRELATION WITH MORPHOLOGIC GRADE AND SURVIVAL** *CANCER*  
Medeiros, L. J., Picker, L. J., Horning, S. J., Warnke, R. A.  
1988; 61 (9): 1844-1851